Clinical Trial Update: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) [Phase 3]

View source ↗

Summary

Phase 3 study MK-0822-018 in postmenopausal osteoporosis was terminated; Merck Sharp & Dohme posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• MK-0822

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: TERMINATED | Results posted: 2019-11-14